Trial: 202011085

OLDER NON-SMALL CELL LUNG CANCER PATIENTS (>/= 70 YEARS
OF AGE) TREATED WITH FIRST-LINE MK-3475 (PEMBROLIZUMAB)
+/- CHEMOTHERAPY (ONCOLOGISTS/PATIENTS CHOICE)

Phase

II

Principal Investigator

Morgensztern, Daniel

Disease Site

Lung; Lung Cancer – Non-small Cell

Learn more about this study at: clinicaltrials.gov